BMO Capital analyst M. Ian Somaiya reiterated an Outperform rating and $221 price target on Intercept Pharmaceuticals (NASDAQ: ICPT), telling ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE